Microfluidic Manufacture of Solid Lipid Nanoparticles: A case study on tristearin-based systems

Dataset

Description

This data supports the work published in this study.

Figure 1. Microfluidic and solid lipid nanoparticles publications in engineering, multidisciplinary, and biology and medicine journals from 1980 to 2019.
Figure 2. A) Size (columns) and PDI (dots) and B) Intensity plot of SLNs made by Nanoassemblr and sized after dialysis purification method. FRR 1:1 (black solid line), 3:1 (black dashed line) and 5:1(gray solid line) were represented and C) Zeta-potential of Tristearin: mPEG-DSPE SLNs using Nanoassemblr after dialysis. Formulations with TFR 10 mL/min and FRR from 1:1 to 5:1 had been tested. Results are expressed as the means of three experiments ± S.D.

Figure 3. Purification of SLNs. Formulations were prepared using a TFR of 10 mL/min and FRR of 1:1. A) Lipid recovery of Tristearin: mPEG-DSPE SLNs after spin column, dialysis and TFF purification and B) Residual solvent after spin column, dialysis and TFF expressed as percentage of remained ethanol (mL%). All data were normalised by IPA standard peaks area. Results are expressed as the means of three experiments ± S.D.

Figure 4. The effect of digestion method on entrapment. Solid lipid nanoparticles encapsulating 0.1, 0.5 and 1 mg/mL initial OVA content were formulated using the Nanoassemblr platform. A) Protein encapsulation efficiency was determined after 3 min, 6 hours and 24 hours post IPA digestion. Protein incorporation also expressed as B) Protein loading efficiency (%) and C) Loading capacity (wt OVA/wt Tristearin). Results are expressed as the means of at least four experiments ± SD.

Figure 5. A) Size (columns), PDI (dots), B) Zeta potential and C) Loading capacity (µg/mL) of OVA loaded SLNs. Initial protein concentration was 0.5 mg/mL. FRR was set up at 3:1 while TFR were increased between 5 and 20 mL/min. Results are expressed as the means of at least four experiments ± SD.

Figure 6. A) The cumulative release profile of OVA under physiological conditions from SLNs (PBS buffer, pH = 7.4, at 37°C). B) Data was also replotted according to first-order models. Results represent percentage cumulative release of initially incorporated OVA and are expressed as the means of three experiments ±SD.
Date made available1 Jul 2019
PublisherUniversity of Strathclyde

Cite this

Perrie, Y. (Creator), Anderluzzi, G. (Contributor). (1 Jul 2019). Microfluidic Manufacture of Solid Lipid Nanoparticles: A case study on tristearin-based systems. University of Strathclyde. Anderlussi_et_al_2019_data_set(.xlsx). 10.15129/be99c1b7-3610-4e7a-b796-1f23890b02b1